HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF) (“HYTN” or the “Company”), a pharmaceutical manufacturer specializing in products containing psychoactive and psychotropic compounds, ...
HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF) ("HYTN" or the "Company"), a pharmaceutical manufacturer specializing in ...
The US Food and Drug Administration (FDA) recently issued three warning letters to facilities in China, the US, and India for ...
Explore key questions on contamination control strategies to support regulatory compliance and risk management in ...
A new injectable therapy, 'Snoretox-1,' is being tested as a safer, more affordable alternative to surgery for flat-faced ...
For pharmaceutical and life sciences companies ready to embrace this moment, the 10 principles aren't a burden. They're a ...
Looking to clarify its expectations on manufacturer responses following inspections, the FDA earlier this year unveiled, for ...
New solutions include customized reagents that scale from bench to clinical trials, industrialized lentiviral vector ...
CDSCO proposed the system in January 2026 as part of an amendment to the New Drugs and Clinical Trial Rules, 2019. The system ...
A nationwide recall has been issued for multiple drugs used in hospital settings after they failed to meet Food and Drug ...
At INTERPHEX 2026, George Kwiecinski examines FDA GMP inspection trends, supplier oversight gaps, and the rising regulatory ...
The Company reported over NIS 270 million in revenue, NIS 37 million in Net loss, NIS 47 million in Adjusted EBITDA and NIS 17 million in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results